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ABSTRACT: In this study we typed HLA class I and II antigens in a series of patients presenting
with the distinct major clinical manifestations of rheumatic fever (RF), i.e, chorea, carditis or arthritis.
Ninety-one patients with RF were evaluated for HLA-A, -B and -DR antigens. Thirty- three had pure
chorea, 26 pure carditis, 16 pure arthritis, and 16 carditis plus arthritis. HLA antigens were typed
by a complement-dependent microlymphocytotoxicity assay. HLA-B49 and HLA-DR1 antigens were
overrepresented in the total group of patients with RF and in all the subgroups studied, excluding
the chorea subgroup in which the frequency of HLA-DR1 antigen was not increased. The results
reported here indicate that immunogenetic susceptibility to RF may vary according to the major
clinical manifestation presented by the patient.
UNITERMS: HLA Antigens. Rheumatic Fever. Chorea. Myocarditis. Arthritis.
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2. PATIENTS AND METHODS
2.1. Patients
Ninety-one patients (31 men) aged 10 to 55 years
(median= 21) with RF, seen at the University Hospital
of the School of Medicine of Ribeirão Preto, São Pau-
lo, Brazil, were typed for HLA antigens. Thirty-three
patients (24 women) aged 11-35 years (median= 18)
presented  rheumatic chorea as the sole manifestation
of the disease, 26 patients (10 men)  aged 12-55 years
(median= 28.5) presented only carditis, 16 patients (8
men) aged 10-39 years (median= 21) presented only
arthritis, and 16 patients (12 women) aged 13-51
(median= 36) presented carditis and arthritis. Although
the patients were studied during the chronic phase
of their disease, all of them fulfilled the revised Jones
criteria(4) for the diagnosis of rheumatic fever at any
time during their follow-up of at least 5 years. All
patients were regularly submitted to cardiac auscultation,
1. INTRODUCTION
It is suggested that rheumatic fever (RF) is a
reactive disorder caused by immune responses against
streptococcal antigens which cross-react with self
antigens, producing autoimmune disease by the
molecular mimicry mechanism(1).  Since cross-reactions
between various group A streptococcal antigens and
autologous human tissues, including myocardium,
myocardial cell membranes, cardiac myosin, heart
sarcolemmal membranes, heart valves, cytoplasm
components of caudate and subthalamic neurons and
articular cartilage structures have been documented(2,3),
it is possible that different HLA molecules may be
involved in the presentation of peculiar streptococcal
antigens, producing distinct clinical manifestations such
as carditis, chorea, arthritis and so forth. In this study,
we evaluated HLA antigens in a large group of patients
with RF presenting only chorea or only carditis or only
arthritis or a combination of arthritis and carditis.
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electrocardiograph and echocardiograph. Chorea was
diagnosed on the basis of clinical features of choreic
movements, emotional lability and hypotonia, after
excluding other causes of chorea.
The study protocol was performed in accordance
with the guidelines the Ethical Committee of the
University Hospital of Ribeirão Preto, and informed
consent was obtained from all subjects prior to their
inclusion in this study.
2.2. Controls
We evaluated 100 normal individuals from the
same geographical area and presenting a similar ethnic
background in relation to patients.
2.3. HLA typing
Mononuclear peripheral cells were isolated using
a Ficoll-Hypaque gradient density. B-lymphocytes were
obtained by adherence to nylon wool. HLA typing was
performed by a standard complement-dependent
microlymphocytotoxicity assay (5), using a panel of 97
antisera which defined 50 HLA-A, -B and -DR
specificities.
2.4. Statistical analysis
HLA frequencies observed in patients and
controls were compared using the two-tailed Fisher’s
Exact test, correcting the p value (pc) according to the
number of specificities tested and the number of
comparisons performed. Differences were considered
significant at pc < 0.05. The relative risk (RR), which
indicates how many times more often the disease occurs
in individuals with the HLA marker compared to those
without it, and the etiologic fraction (EF), which
indicates the attributable risk at the population level,
were also estimated (6).
3. RESULTS
Among the HLA class I antigens, only HLA-
B49 was significantly increased in the RF patients as a
whole (12%) and in the subsets presenting with chorea
(15%), arthritis (19%) or carditis (8%), compared to
none of the controls. Although the RR for HLA-B49
antigen was correspondingly high (9.72 to 26.05), the
generally low frequency of this antigen in the patient
group yielded a uniformly low EF (0.06 to 0.18) for
all groups studied (Tables I and II).
Table I - Frequency of relevant HLA -B and -DR antigens in the total group of patients with rheumatic
fever, and in those presenting the following features: only chorea, only carditis, only arthritis, carditis
plus arthritis, and normal individuals. Subgroups encompassing patients with carditis or arthritis or
both, and carditis or arthritis are also shown
Total
Group
(n=91)
Only
Chorea
(n=33)
Only
Carditis
(n=26)
Only
Arthritis
(n=16)
Carditis
plus
Arthritis
(n=16
Carditis  or
Arthritis or
both
(n=58)
Carditis or
Arthritis
(n=42)
Normal
Individuals
(n=100)HLA
N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%)
B49
DR1
DR2
DR3
DR4
DR5
DR6
DR7
DR8
DR9
DR10
11
46
30
39
22
23
3
6
4
0
0
12
50
33
43
24
25
3
7
4
0
0
5
9
11
18
6
10
0
2
4
0
0
15
27
33
54
18
30
0
6
12
0
0
2
15
8
10
4
9
1
2
0
0
0
8
58
31
38
15
35
4
8
0
0
0
3
10
6
6
5
2
1
2
0
0
0
19
62
37
37
31
12
6
12
0
0
0
1
12
5
5
7
2
1
0
0
0
0
6
75
31
31
43
12
6
0
0
0
0
6
37
19
21
16
13
3
4
0
0
0
10
64
33
36
27
22
5
7
0
0
0
5
25
14
16
9
11
2
4
0
0
0
12
59
33
38
21
26
5
9
0
0
0
0
26
31
28
23
20
6
21
2
2
0
0
26
31
28
23
20
6
21
2
2
0
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population level is low. Other studies conducted on
Caucasian, Maori, Mexican and Japanese patients with
rheumatic heart  disease included the class I specificities
HLA-A29, -A30, -A31; HLA-A3 and -B8; HLA-B22;
HLA-B5; and  HLA-B18 and -B35 as susceptibility
markers(7/10). In addition, there is only one study
evaluating HLA antigens in a small subgroup (9
Caucasians and 4 North-American Blacks) of patients
with chorea in which no association with HLA class I
antigens was found (11).
The literature findings regarding HLA class II
antigens are heterogeneous according to the population
studied and to the form of disease presentation. We
showed that the frequency of HLA-DR1 antigen was
closely similar in patients presenting with carditis,
arthritis or both, suggesting a shared marker for these
clinical manifestations, in contrast to chorea in which
the  HLA-DR1 frequency was closely related to that of
controls. Similarly, Monplaisir et al.(12) reported that
HLA-DR1 antigen is increased in patients with RF from
Martinique, regardless of the clinical manifestation.
Rheumatic heart disease is associated with HLA-DR1
and HLA-DR6 antigens in South-African Blacks(13),
HLA-DR2 antigen in North-American Blacks(11), HLA-
DR3 antigen in the Indian population(14), HLA-DR4
antigen in North-American Caucasians(11), and Saudi
Arabians(15). In a recent collaborative study
encompassing almost 300 patients with RF, irrespective
Fifty percent of the RF patients carried the HLA-
DR1 specificity, compared to 26% of controls (pc =
0.015). Although statistical significance was lost after
correction of the p value among the subsets of RF, HLA-
DR1 antigen frequency varied in subgroups, being 64%
in patients with carditis or arthritis or both, and even
higher (75%) in the carditis plus arthritis subset.
Interestingly, only 27% of the patients with chorea
carried the HLA-DR1 antigen, a value which is identical
to controls. With the exception of the chorea subset in
which the RR was 1.06, the RR conferred by HLA-
DR1 antigen ranged from 2.9 to 8.5 yielding distinct
values of EF for each subset of the disease. Although
the frequency of HLA-DR3 and HLA-DR8 antigens
tended to be increased in the chorea subgroup, no other
HLA class II specificity was significantly associated
with RF as a whole or RF subsets (Tables I and II).
4. DISCUSSION
Regarding HLA class I specificities, only HLA-
B49 antigen was increased in the total group and in the
subgroups of RF patients studied here. Because of the
lack of HLA-B49 antigen in controls and the relatively
low frequency of this antigen in patients, the estimation
of the EF for this antigen in the total group and in the
subgroups showed values of about 10%, which means
that the susceptibility conferred by this antigen at the
Table II - Uncorrected and corrected p value (pc), relative risk (RR) and etiologic fraction (EF) for
serologically defined HLA specificities in patients with rheumatic fever (total group and other clinically
defined subsets)
Total Group
(n=91)
Only
Chorea
(n=33)
Only
Carditis
(n=26)
Only
Arthritis
(n=16)
Carditis plus
Arthritis
(n=16)
Carditis or
Arthritis or
both  (n=58)
Carditis or
Arthritis
(n=42)
HLA-B49
P
Pc
RR
EF
< 0.001
0.01
14.35
0.11
< 0.001
< 0.001
19.39
0.14
0.04
NS
10.2
0.07
0.002
NS
26.05
0.18
< 0.001
< 0.001
9.72
0.06
0.002
NS
12.44
0.09
< 0.001
< 0.001
14.74
0.11
HLA-DR1
P
Pc
RR
EF
< 0.001
0.015
2.91
0.33
0.6
NS
1.06
0.015
0.002
NS
3.18
0.39
0.005
NS
4.74
0.49
< 0.001
NS
8.54
0.66
< 0.001
0.001
5.01
0.51
< 0.001
NS
4.18
0.45
EA Donadi; PPC Lamparelli; LZ Figueiredo; CM Paula-Santos  & JC Voltarelli
58
of the major clinical manifestations of the disease,
showed association with HLA-DR4 antigen in
Egyptians, and increased prevalence of HLA-DR4 and
-DR7 in Indians and Mexicans(16). In Brazilians, a
previous study by Guilherme et al(17) reported an
increased frequency of the HLA-DR7 antigen in patients
with RF as a whole from several regions of Brazil;
however, further studies encompassing a larger group
of patients did not confirm such an association (16).
Discrepancies between their results and ours may be
related  to regional population differences and to the
lack of patient selection according to clinical
manifestations. Regarding  the HLA class II
associations with rheumatic chorea, we did not find
reports solely focusing on this manifestation; however,
Ayoub et al (11) studying a large group of RF patients,
of whom only 9 Black and 4 Caucasian presented pure
chorea, showed no association with any HLA class II
antigens after correction of the p values.
Although we did not define any novel HLA class
II association with chorea, other studies describe
different markers for RF. A B cell alloantigen, identified
by the monoclonal antibody D8/17, which did not
appear to be associated with any known MHC antigen,
is observed in rheumatic heart disease patients and their
families(18), and in some patients with chorea (19). The
relationship between this B cell antigen and the
immunogenetic susceptibility to RF has not been
established. A study of HLA alleles using restriction
fragment length polymorphism conducted on Brazilian
patients with RF, most of them presenting heart disease,
reported a significant association of a 13.83 kb
fragment upon Taq I digestion and hybridization with
a cDNA probe for the DRB gene, which was correlated
with the HLA-DR53 and -DR16 specificities (20).
Susceptibility to rheumatic fever has not been
extensively studied as other autoimmune disorders such
as insulin-dependent diabetes mellitus (IDDM) or adult
rheumatoid arthritis; however, the findings reported for
these diseases may help us understand those reported
for rheumatic fever. IDDM is highly associated with
HLA-DQB1*0302 in several Caucasian and non-
Caucasian populations (21), and the molecule per se may
play a role in selecting the “diabetogenic peptide” which
is presented to autoreactive lymphocytes (22). In contrast,
in rheumatoid arthritis, a unique stretch of amino acids
shared by some HLA molecules known as “shared
epitope” is suggested to be associated with susceptibility
to the disease. It has also been suggested that for IDDM
this association lies at the peptide contact site of the
HLA class II molecule, whereas for rheumatoid arthritis
the shared epitope region of the HLA class II molecule
may be involved in direct T-cell-HLA interactions (21).
Regarding RF, none of these models of association of
HLA molecules and disease appears to be adequate.
Rheumatic heart disease is associated with a vast array
of HLA class II antigens in patients of distinct ethnic
backgrounds; however, chorea is not associated with any
of these antigens(23). Although much has to be learned
about susceptibility to RF, the findings reported here
suggest that the immunogenetic susceptibility to RF may
differ according to the form of disease presentation.
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RESUMO: Antígenos HLA de classe I (HLA-A e HLA-B) e II (HLA-DR) foram tipificados em
um grupo de 91 pacientes com as principais formas de apresentação da febre reumática, ou seja,
coréia, cardite ou artrite. Desses pacientes, 33 tinham apenas coréia, 26 apenas cardite, 16 ape-
nas artrite e 16 cardite e artrite. Os antígenos HLA foram tipificados, utilizando-se o teste de
microlinfocitotoxicidade dependente de complemento. As freqüências dos antígenos HLA-B49 e
HLA-DR1 estavam significantemente aumentadas nos pacientes, quando considerados como um
todo, e, ainda, em todos os subgrupos estudados, excetuando-se aquele com coréia, no qual a
freqüência do antígeno HLA-DR1 não estava aumentada. Esses resultados indicam que a sus-
ceptibilidade imunogenética à febre reumática pode variar de acordo com as manifestações clíni-
cas, apresentadas pelos pacientes.
UNITERMOS: Antígenos HLA. Febre Reumática. Coréia. Miocardite. Artrite.
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